Table 3.
Variable | Serious COVID-19 illness | ||
---|---|---|---|
RR | 95% CI | P | |
Children | |||
Hydroxyurea | 0.91 | 0.56-1.47 | .69 |
Prior acute care visits for pain,* >2 vs 0 | 3.09 | 1.59-6.03 | .0009 |
SCD renal† | 3.67 | 1.93-6.96 | <.0001 |
SCD heart/lung‡ | 1.76 | 1.06-2.92 | .03 |
Adults | |||
Age | 1.04 | 1.01-1.06 | .002 |
Hydroxyurea | 0.85 | 0.49-1.51 | .59 |
Prior acute care visits for pain,* >2 vs 0 | 1.94 | 1.11-3.40 | .02 |
P < .05 was considered significant.
*Hospitalization and/or ED treat-and-release visit requiring IV opioids for pain in the last 3 years.
†Albuminuria, decreased renal function, and/or SCD nephropathy.
‡Acute chest syndrome in the last 3 years and/or pulmonary hypertension.
None of the other covariates were significant (SCD brain, non-SCD neurobehavioral, non-SCD lung, non-SCD heart comorbidities).